• 1
    Mcgee D.J., Mobley H.L. (2000) Pathogenesis of Helicobacter pylori infection. Curr Opin Gastroenterol 16 : 2431.
  • 2
    Axon A.T. (1998) Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives. Gut 43(Suppl 1): S703.
  • 3
    Todoroki I., Joh T., Watanabe K., Miyashita M., Seno K., Nomura T., Ohara H., Yokoyama Y., Tochikubo K., Itoh, M. (2000) Suppressive effects of DNA vaccines encoding heat shock protein on Helicobacter pylori-induced gastritis in mice. Biochem Biophys Res Commun 277 : 15963.
  • 4
    Miyashita M., Joh T., Watanabe K., Todoroki I., Seno K., Ohara H., Nomura T., Miyata M., Kasugai K., Tochikubo K., Itoh M., Nitta, M. (2002) Immune responses in mice to intranasal and intracutaneous administration of a DNA vaccine encoding Helicobacter pylori-catalase. Vaccine 20 : 233642.
  • 5
    Hatzifoti C., Roussel Y., Harris A.G., Wren B.W., Morrow J.W., Bajaj-Elliott M. (2006) Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori. Helicobacter 11 : 11322.
  • 6
    Hatzifoti C., Bajaj-Elliott M., Dorrell N., Anyim M., Prentice M.B., Nye K.E., Wren B., Morrow W.J. (2004) A plasmid immunization construct encoding urease B of Helicobacter pylori induces an antigen-specific antibody response and upregulates the expression of beta-defensins and IL-10 in the stomachs of immunized mice. Vaccine 22 : 26519.
  • 7
    Begue R.E., Cruz A.R., Ramgoolam A., Breslin M.B. (2007) Immunogenicity of Helicobacter pylori urease B protein and DNA vaccines in a mouse model. J Pediatr Gastroenterol Nutr 45 : 4936.
  • 8
    Summerton N.A., Welch R.W., Bondoc L., Yang H.H., Pleune B., Ramachandran N., Harris A.M., Bland D., Jackson W.J., Park S., Clements J.D., Nabors G.S. (2010) Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28 : 140411.
  • 9
    Flach C.-F., Svensson N., Blomquist M., Ekman A., Raghavan S., Holmgren J. (2011) A truncated form of HpaA is a promising antigen for use in a vaccine against Helicobacter pylori. Vaccine 29 : 123541.
  • 10
    Yamaoka Y., Kwon D.H., Graham D.Y. (2000) A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 97 : 75338.
  • 11
    Ben Mansour K., Fendri C., Zribi M., Masmoudi A., Labbene M., Fillali A., Ben Mami N., Najjar, T., Meherzi, A., Sfar, T., Burucoa C. (2010) Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients. Ann Clin Microbiol Antimicrob 9 : 10.
  • 12
    Sheu B.S., Yang H.B., Yeh Y.C., Wu J.J. (2010) Helicobacter pylori colonization of the human gastric epithelium: a bug's first step is a novel target for us. J Gastroenterol Hepatol 25 : 2632.
  • 13
    Pun, P.B., Bhat, A.A., Mohan, T., Kulkarni, S., Paranjape, R., Rao, D.N. (2009) Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 9 : 46877.
  • 14
    Wang X., Zhang X., Kang Y., Jin H., Du X., Zhao G., Yu Y., Li J., Su B., Huang C., Wang B. (2008) Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine 26 : 513544.
  • 15
    Aggarwal P., Kumar S., Vajpayee M., Seth P. (2005) Adjuvant action of murine IL-2/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant 120 construct. Viral Immunol 18 : 64956.
  • 16
    Yang X.L., Liu W.C., Yang W.W., Zhong D., Liu Y.H., Zhang J.D., Jiang J.H., Li S.S. (2005) Oral immunization of mice with vaccine of attenuated Salmonella typhimurium expressing Helicobacter pylori urease B subunit. Biomed Environ Sci 18 : 4118.
  • 17
    Velin D., Michetti P. (2010) Advances in vaccination against Helicobacter pylori. Expert Rev Gastroenterol Hepatol 4 : 15766.
  • 18
    Molnar B., Galamb O., Sipos F., Leiszter K., Tulassay, Z. (2010) Molecular pathogenesis of Helicobacter pylori infection: the role of bacterial virulence factors. Dig Dis 28 : 6048.
  • 19
    Garhart C.A., Heinzel F.P., Czinn S.J., Nedrud, J.G. (2003) Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect Immun 71 : 91021.
  • 20
    Gottwein J.M., Blanchard T.G., Targoni O.S., Eisenberg J.C., Zagorski B.M., Redline R.W., Nedrud J.G., Tary-Lehmann M., Lehmann P.V., Czinn S.J. (2001) Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis 184 : 30814.
  • 21
    Taylor J.M., Ziman M.E., Canfield D.R., Vajdy M., Solnick J.V. (2008) Effects of a Th1- versus a Th2-biased immune response in protection against Helicobacter pylori challenge in mice. Microb Pathog, 44 : 207.
  • 22
    Taylor J.M., Ziman M.E., Huff J.L., Moroski N.M., Vajdy M., Solnick J.V. (2006) Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice. Vaccine 24 : 498794.
  • 23
    Shi T., Liu W.Z., Gao F., Shi G.Y., Xiao S.D. (2005) Intranasal CpG-oligodeoxynucleotide is a potent adjuvant of vaccine against Helicobacter pylori, and T helper 1 type response and interferon-gamma correlate with the protection. Helicobacter 10 : 719.
  • 24
    Blanchard T.G., Eisenberg J.C., Matsumoto Y. (2004) Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine 22 : 88897.
  • 25
    Lin F., Shen X., Mccoy J.R., Mendoza J.M., Yan J., Kemmerrer S.V., Khan A.S., Weiner D.B., Broderick K.E., Sardesai N.Y. (2011) A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine 29 : 677180.
  • 26
    Maeda K., Yamashiro T., Minoura T., Fujioka T., Nasu M., Nishizono A. (2002) Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection. Microbiol Immunol 46 : 61320.
  • 27
    Rodrigues J.F., Mathias-Santos C., Sbrogio-Almeida M.E., Amorim J.H., Cabrera-Crespo J., Balan A., Ferreira L.C. (2011) Functional diversity of heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli: differential enzymatic and immunological activities of LT1 (hLT) AND LT4 (pLT). J Biol Chem 286 : 522233.
  • 28
    Da Silva Ramos Rocha A., Conceicao F.R., Grassmann A.A., Lagranha V.L., Dellagostin O.A. (2008) B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination. Can J Microbiol 54 : 67786.
  • 29
    Kim T.G., Kim B.G., Kim M.Y., Choi J.K., Jung E.S., Yang M.S. (2010) Expression and immunogenicity of enterotoxigenic Escherichia coli heat-labile toxin B subunit in transgenic rice callus. Mol Biotechnol 44 : 1421.
  • 30
    Fingerut E., Gutter B., Goldway M., Eliahoo D., Pitcovski J. (2006) B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet Immunol Immunopathol 112 : 25363.
  • 31
    Fingerut E., Gutter B., Meir R., Eliahoo D., Pitcovski J. (2005) Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine 23 : 468596.
  • 32
    Marshall D.J., Rudnick K.A., Mccarthy S.G., Mateo L.R., Harris M.C., Mccauley C., Snyder L.A. (2006) Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine 24 : 24453.
  • 33
    Min W., Lillehoj H.S., Burnside J., Weining K.C., Staeheli P., Zhu J.J. (2001) Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 20 : 26774.
  • 34
    O’donovan L.H., Mcmonagle E.L., Taylor S., Bain D., Pacitti A.M., Golder M.C., Mcdonald M., Hanlon L., Onions D.E., Argyle D.J., Jarrett O., Nicolson L. (2005) A vector expressing feline mature IL-18 fused to IL-1beta antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus. Vaccine 23 : 381423.
  • 35
    Sakai T., Hisaeda H., Nakano Y., Zhang M., Takashima M., Ishii K., Maekawa Y., Matsumoto S., Nitta Y., Miyazaki J., Yamamoto S., Himeno K. (2003) Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine 21 : 143244.
  • 36
    Sommer F., Wilken H., Faller G., Lohoff M. (2004) Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun 72 : 102935.
  • 37
    Liu L., Zhou X., Liu H., Xiang L., Yuan Z. (2005) CpG motif acts as a ‘danger signal’ and provides a T helper type 1-biased microenvironment for DNA vaccination. Immunology 115 : 22330.
  • 38
    Begue R.E., Sadowska-Krowicka H. (2010) Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol 60 : 1426.
  • 39
    Akhiani A.A., Pappo J., Kabok Z., Schon K., Gao W., Franzen L.E., Lycke N. (2002) Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J Immunol 169 : 697784.
  • 40
    Taylor J.M., Ziman M.E., Fong J., Solnick J.V., Vajdy M. (2007) Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun 75 : 34629.
  • 41
    Akhiani A.A., Stensson A., Schon K., Lycke N.Y. (2005) IgA antibodies impair resistance against Helicobacter pylori infection: studies on immune evasion in IL-10-deficient mice. J Immunol 174 : 814453.